SCHEMBL710279

SCHEMBL710279

CCCn1cnc(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 3/20 0.54
KDM5B Q9UGL1 3/20 0.54
PLA2G4A P47712 1/20 0.46
CPB2 Q96IY4 8/20 0.46
CPB1 P15086 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 2/20 0.40
SMYD3 Q9H7B4 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
THPO P40225 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2283649 0.89 PLA2G4A (0.50) KDM5AKDM5BPLA2G4ACPB2CPB1
SCHEMBL30268827 0.88 PLA2G4A (0.52) KDM5AKDM5BPLA2G4ACPB2CPB1
SCHEMBL27781577 0.86 PLA2G4A (0.54) KDM5AKDM5BPLA2G4ACPB2CPB1
SCHEMBL27781551 0.86 PLA2G4A (0.54) KDM5AKDM5BPLA2G4ACPB2CPB1
SCHEMBL151394 0.85 SMYD3 (0.50) KDM5AKDM5BPLA2G4ACPB2CPB1
SCHEMBL6335386 0.84 KDM5A (0.46) KDM5AKDM5BPLA2G4ACPB2CPB1
SCHEMBL7265607 0.83 PLA2G4A (0.39) KDM5AKDM5BPLA2G4ACPB2KDM4E
SCHEMBL2282033 0.81 CPB2 (0.45) KDM5AKDM5BPLA2G4ACPB2CPB1
SCHEMBL28934829 0.80 NOTUM (0.49) KDM5AKDM5BCPB2CPB1KDM4E
SCHEMBL3689829 0.79 PLA2G4A (0.40) KDM5AKDM5BPLA2G4AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
US-20250214984-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2025-07-03 US disclosed
EP-4146645-B1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2025-06-25 EP disclosed
US-12269817-B2 Compound having KDM5 inhibitory activity and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2025-04-08 US disclosed
EP-4471027-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO Pharmaceutical Co., Ltd. (JP) 2024-12-04 EP disclosed
CN-115461338-B 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof 小野药品工业株式会社 2024-02-20 CN disclosed
US-20230271952-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2023-08-31 US disclosed
US-11691968-B2 Compound having KDM5 inhibitory activity and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2023-07-04 US disclosed
US-20230109293-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2023-04-06 US disclosed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
CN-101679293-A Urocanic acid derivatives useful for the treatment of immune-related and inflammatory diseases VALETTA HEALTH B V 2010-03-24 CN disclosed
EP-1898903-A2 INHIBITORS OF AKT ACTIVITY Merck & Co., Inc. (US) 2008-03-19 EP disclosed
WO-2006135627-A2 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2006-12-21 WO disclosed
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12269817-B2 Compound having KDM5 inhibitory activity and pharmaceutical use thereof KDM5A, KDM5B, KDM5D KDM5A 1/4885KDM5B 2/4885PLA2G4A 3408/4885
US-20100222321-A1 Inhibitors of akt activtiy PIK3CA, PIK3CD, INPP5D KDM5A 1189/4885KDM5B 1806/4885PLA2G4A 765/4885
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 KDM5A 2715/4885KDM5B 3724/4885PLA2G4A 2510/4885
US-11691968-B2 Compound having KDM5 inhibitory activity and pharmaceutical use thereof KDM5A, KDM5B, KDM5D KDM5A 1/4885KDM5B 2/4885PLA2G4A 3408/4885
US-20250214984-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF KDM5A, KDM5B, KDM5D KDM5A 1/4885KDM5B 2/4885PLA2G4A 3408/4885
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors SLC1A2, SLC1A1, GLRA1 KDM5A 2993/4885KDM5B 3951/4885PLA2G4A 2340/4885
US-20230109293-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF KDM5A, KDM5B, KDM5D KDM5A 1/4885KDM5B 2/4885PLA2G4A 3408/4885
US-20230271952-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF KDM5A, KDM5B, KDM5D KDM5A 1/4885KDM5B 2/4885PLA2G4A 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.